吸入沙美特罗/替卡松粉剂对稳定期COPD患者血清visfatin浓度的影响

目的 探讨吸入沙美特罗/替卡松粉剂对慢性阻塞性肺病（COPD）稳定期患者血清内脂素（visfatin）浓度的影响.方法 选择Ⅲ级及Ⅳ级稳定期COPD患者84例,随机分为单纯吸入沙美特罗（50μg）及沙美特罗/替卡松粉剂（50μg/500μg）两组,每组42例,每日吸入2次,每次1吸,疗程8周.收集治疗前后血清标本各1份,采用ELISA法检测患者血清visfatin浓度.结果 治疗前后平均血清visfatin浓度吸入沙美特罗/替卡松粉剂治疗组患者分别为（26.1±6.5） ng/ml和（17.2±5.3） ng/ml,治疗前后血清平均visfatin水平差异有统计学意义（P＜0.05）.单纯吸入沙美特罗/粉剂组治疗前后患者血清visfatin浓度分别为（27.5±6.9）ng/ml和（26.7±6.5）ng/ml,治疗前后血清平均visfatin水平差异无统计学意义（P＞0.05）.结论 稳定期COPD患者吸入沙美特罗/替卡松粉剂治疗,血清visfatin浓度比治疗前降低,血清visfatin浓度检测可成为一个潜在的COPD治疗的生物学检测指标.

Effect of inhaled salmeterol/fluticasone on serum visfatin in individuals with stable chronic obstructive pulmonary disease

[Abstract] Objective To determine the effect of inhaled salmeterol/fluticasone on serum visfatin in individuals with stable chronic obstructive pulmonary disease. Methods 84 COPD patients were randomly divided ;.nto two groups. Group 1 （n=42） were treated with salmeterol （50μg） alone, and group 2 （n=42） with salmetero fluticasone（5Ovg/ 500vg）. Each patient inhaled twice daily and inhaled each day for 8 weeks. Serum samples were taken at baseline and 8 weeks after treatment. The levels of serum visfatin were detected in the method of ELISA. Results The average serum visfatin for patients were significantly decreased from 26.1±6.5ng]ml to 17.2±5.3ng/ml （P〈0. 05） in patients inhaled salmeterol/fluticasone. The average serum visfatin for patients inhaled salmeterol alone was 27.5±6.9ng/ml and 26.7±6.5ng/ml at baseline and after inhaled salmeterol were not difference（P〉0.05）. Conclusion The serum visfatin in patients with stable COPD inhaled salmeterol/fluticasone decrease significantly and may be a potential diagnostic biomarker for COPD treatment.